Effectiveness and safety of the combination therapy of micro-needling and minoxidil in androgenetic alopecia of Indonesian men: a randomized controlled trial

IF 2.3 Q2 DERMATOLOGY Dermatology Reports Pub Date : 2024-02-06 DOI:10.4081/dr.2024.9945
Kara Adistri, Sondang P. Sirait, Rahadi Rihatmadja, Lili Legiawati, Wresti Indriatmi, Siti Rizny Fitriana Saldi
{"title":"Effectiveness and safety of the combination therapy of micro-needling and minoxidil in androgenetic alopecia of Indonesian men: a randomized controlled trial","authors":"Kara Adistri, Sondang P. Sirait, Rahadi Rihatmadja, Lili Legiawati, Wresti Indriatmi, Siti Rizny Fitriana Saldi","doi":"10.4081/dr.2024.9945","DOIUrl":null,"url":null,"abstract":"Introduction: Androgenetic alopecia (AGA) is the most common type of hair loss. Treatment options are limited. Microneedling, a minimally invasive technique can enhance hair growth by releasing growth factors. However, standardized protocol regarding the frequency, depth and duration has not been available. This study aims to determine the effectiveness and safety of the combination therapy of microneedling and minoxidil in AGA. Methods: This study was a randomized controlled clinical trial conducted over 12 weeks. Intervention group: a combination therapy of 4-weekly microneedling and 5% minoxidil, and control group got topical 5% minoxidil alone. Hair density and diameter were assessed using FotoFinder® trichoscale every 4 weeks. Results: A total of 36 male participants, between 26-51 years old, with Hamilton-Norwood type III-VI AGA were included. At the end of study, a significant increase in hair density was observed in the intervention group compared to control (95.6 vs 52.4 hair/cm², p<0.001), as was in hair diameter (18 vs 6 μm, p=0.004). Side effects, included itching and transient erythema, were well tolerated. Conclusion: The combination of 4-weekly microneedling and topical 5% minoxidil is effective in increasing both hair density and hair diameter, and safe to use in AGA patients.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/dr.2024.9945","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Androgenetic alopecia (AGA) is the most common type of hair loss. Treatment options are limited. Microneedling, a minimally invasive technique can enhance hair growth by releasing growth factors. However, standardized protocol regarding the frequency, depth and duration has not been available. This study aims to determine the effectiveness and safety of the combination therapy of microneedling and minoxidil in AGA. Methods: This study was a randomized controlled clinical trial conducted over 12 weeks. Intervention group: a combination therapy of 4-weekly microneedling and 5% minoxidil, and control group got topical 5% minoxidil alone. Hair density and diameter were assessed using FotoFinder® trichoscale every 4 weeks. Results: A total of 36 male participants, between 26-51 years old, with Hamilton-Norwood type III-VI AGA were included. At the end of study, a significant increase in hair density was observed in the intervention group compared to control (95.6 vs 52.4 hair/cm², p<0.001), as was in hair diameter (18 vs 6 μm, p=0.004). Side effects, included itching and transient erythema, were well tolerated. Conclusion: The combination of 4-weekly microneedling and topical 5% minoxidil is effective in increasing both hair density and hair diameter, and safe to use in AGA patients.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
微针和米诺地尔联合疗法对印尼男性雄激素性脱发的有效性和安全性:随机对照试验
简介:雄激素性脱发(AGA)是最常见的脱发类型:雄激素性脱发(AGA)是最常见的脱发类型。治疗方法有限。微针疗法是一种微创技术,可通过释放生长因子促进头发生长。然而,目前还没有关于治疗频率、深度和持续时间的标准化方案。本研究旨在确定微针疗法和米诺地尔联合疗法对 AGA 的有效性和安全性。研究方法本研究是一项随机对照临床试验,为期 12 周。干预组:每4周进行一次微针和5%米诺地尔联合治疗,对照组仅外用5%米诺地尔。每4周使用FotoFinder® Trichoscale评估头发密度和直径。结果研究共纳入了 36 名患有汉密尔顿-诺伍德 III-VI 型 AGA 的男性患者,年龄在 26-51 岁之间。研究结束时,与对照组相比,干预组的毛发密度(95.6 根/平方厘米对 52.4 根/平方厘米,P<0.001)和毛发直径(18 微米对 6 微米,P=0.004)均有显著增加。瘙痒和一过性红斑等副作用的耐受性良好。结论每周 4 次的微针疗法与 5%米诺地尔外用药相结合,可有效增加毛发密度和毛发直径,而且在 AGA 患者中使用安全。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Dermatology Reports
Dermatology Reports DERMATOLOGY-
CiteScore
1.40
自引率
0.00%
发文量
74
审稿时长
10 weeks
期刊最新文献
Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate to severe plaque psoriasis Scabies mimicking relapsing atopic dermatitis Blue diode laser as supportive therapy for the management of vulvar lichen sclerosus “Mosaic graft” technique and surgical dermal glue in Mohs micrographic surgery and general dermatologic surgery Cutaneous larva migrans: is dermoscopy useful for the treatment?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1